Trial Profile
A open-label trial to compare pharmacokinetics and pharmacodynamics of subcutaneous and intravenous administration of natalizumab in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Pharmacokinetics
- 06 Dec 2015 New trial record